hypophosphatemia%20-and-%20hyperphosphatemia
HYPOPHOSPHATEMIA & HYPERPHOSPHATEMIA

Hypophosphatemia is an electrolyte imbalance where there is a decrease in the serum phosphate level that is less than the normal range.

It is recognized most often in critically-ill patients, decompensated diabetics, alcoholics or other malnourished persons, and acute infectious or pulmonary disorders.

It may be transient and reflect intracellular shift with minimal clinical consequences.

Hyperphosphatemia is an electrolyte disturbance in which an increase in the serum phosphate level of more than the normal range is present.

Most symptoms of acute hyperphosphatemia are due to secondary hypocalcemia.

The significant level of hyperphosphatemia in adults is >6 mg/dL.

Hypophosphatemia%20-and-%20hyperphosphatemia Signs and Symptoms

Introduction

Hypophosphatemia is recognized most often in:
  • Critically-ill patients
  • Decompensated diabetics
  • Alcoholics or other malnourished persons
  • Acute infectious or pulmonary disorders
  • Patients who are in IV hyperalimentation without phosphate supplementation
  • Patients with urinary phosphate-wasting syndromes (eg Fanconi syndrome or tumor-induced osteomalacia)

Hyperphosphatemia

  • Defined as an electrolyte disturbance in which an increase in the serum phosphate level of more than the normal range is present

Etiology

Hypophosphatemia 

  • More pronounced when there is underlying phosphate depletion (eg hyperparathyroidism,vitamin D deficiency, alcoholism and glycosuria)
  • Mechanisms that may cause hypophosphatemia:
    • Increased urinary losses due to impaired intestinal absorption
    • Redistribution of phosphate from extracellular fluid into the intracellular space or the mineral phase of bone
    • Removal by renal replacement therapies
    • Severe and selective deprivation of dietary phosphate that rarely occurs

Hyperphosphatemia

  • Decreased Renal Phosphate Excretion
    • Renal failure
    • Hypoparathyroidism
    • Pseudohypoparathyroidism
    • Familial tumoral calcinosis
    • Bisphosphonate therapy
    • Vitamin D intoxication
    • Acromegaly
    • Mg deficiency
  • Others
    • Acid-base disorders
    • Crush injuries
    • Fulminant hepatitis
    • Rhabdomyolysis
    • Artifactual due to hemolysis
    • Extracellular shift from intracellular compartment
    • Chronic Heparin therapy

Signs and Symptoms

Hypophosphatemia
Mild
  • Usually asymptomatic
Moderate-Severe
  • Neurological: Confusion, irritability, apprehension, fatigue, numbness, paresthesia, seizures, coma, metabolic encephalopathy
  • Musculoskeletal: Myalgia and myopathy, muscle weakness, rhabdomyolysis, rickets, osteomalacia
  • Respiratory: Reversible respiratory failure
  • Cardiovascular: Impairment of cardiac contractility, cardiomyopathy
  • Hematological: Hemolysis, thrombocytopenia, impaired phagocytosis
Hyperphosphatemia
Acute - 
Most symptoms are due to secondary hypocalcemia
  • Hypocalcemia
  • Neuromuscular irritability/muscle cramps
  • Tetany
  • Paresthesias
  • Seizures
  • Hypotension
  • Cardiac arrhythmia

Chronic - Persistent hyperphosphatemia (>12 hours) that usually occurs in patients with chronic renal failure and familial tumoral calcinosis

  • Normocalcemia
  • Nephrocalcinosis
  • Soft tissue or vascular calcification
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, Yesterday

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.